[Use of obsidan in patients with myocardial infarction].
An assessment of antiarrhythmic efficiency of obsidan by means of repeated 24-hour ECG monitoring with tape recording was made in 42 patients with a documented anterior transmural and macrofocal myocardial infarction. A marked and significant antiarrhythmic effect of obsidan was demonstrated with respect to most arrhythmias, particularly high-grade ventricular extrasystoles. The drug is shown to have a favorable effect on the size of the peri-infarction++ area. A moderate negative inotropic effect of obsidan did not provoke clinical signs of heart failure. In the absence of contraindications, obsidan is recommended for use since the very first days of myocardial infarction.
T E
TE
Dobrotvorskaia
F M
FM
Mustafaev
Sh S
ShS
Arifullin
D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000517:prevention & control*; D003864:Depression, Chemical; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D011433:Propranolol / Q000627:therapeutic use*
D011433:Propranolol
Primenie obzidana u bo'lnykh infarktom miokarda.